The Pulmonx® solution for treatment of severe emphysema

  • Accurately identifies appropriate patients
    • The Chartis® System enables physicians to identify appropriate candidates for the Zephyr® Endobronchial Valve therapy
  • Offers sustained and meaningful patient benefits
    • The Zephyr valve provides a treatment option that significantly improves lung function, exercise tolerance, and quality of life in patients with severe emphysema
  • Cloud-based quantitative CT analysis
    • The StratX™ analysis quantifies the completeness of each fissure using an algorithm that has been validated in a retrospective study of over 200 EBV patients, the largest such analysis performed to date. Fissure completeness is a proven predictor for volume reduction resulting from EBV® therapy.

Learn more about products in development.